Dec 10, 2013 : Bharat Book Bureau presents the new report, on 'Cancer Monoclonal Antibody Partnering Terms and Agreements' provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 350 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading cancer monoclonal antibody deals
since 2007. Deals are listed by headline value, signed by big pharma, big
biotech and most active of all biopharma companies. Where the deal has an
agreement contract published at the SEC a link provides online access to the
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with deal announcement in cancer monoclonal antibody partnering, with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announcement in cancer monoclonal antibody partnering,with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus, and monoclonal antibody technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.
Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.
Cancer Monoclonal Antibody Partnering Agreements includes:
Trends in cancer monoclonal antibody dealmaking in the biopharma industry since
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 350 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2007
Table of contents :
Chapter 1 – Introduction
Chapter 2 – Trends in cancer monoclonal antibody dealmaking
2.2. Cancer monoclonal antibody partnering over the years
2.3. Big pharma cancer monoclonal antibody dealmaking activity
2.4. Big biotech cancer monoclonal antibody dealmaking activity
2.5. Most active in cancer monoclonal antibody partnering
2.6. Cancer monoclonal antibody partnering by deal type
2.7. Cancer monoclonal antibody partnering by stage of development
2.8. Cancer monoclonal antibody partnering by cancer indication
2.9. Cancer monoclonal antibody partnering by antibody type
2.10. Disclosed deal terms for cancer monoclonal antibody partnering
2.10.1 Cancer monoclonal antibody partnering headline values
2.10.2 Cancer monoclonal antibody deal upfront payments
2.10.3 Cancer monoclonal antibody deal milestone payments
2.10.4 Cancer monoclonal antibody royalty rates
Chapter 3 – Leading cancer monoclonal antibody deals
3.2. Top cancer monoclonal antibody deals by value
Chapter 4 – Big pharma cancer monoclonal antibody deals
4.2. How to use big pharma partnering deals
4.3. Big pharma cancer monoclonal antibody partnering company profiles
Johnson & Johnson
Janssen Pharmaceutica NV
Merck & Co
For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/cancer-monoclonal-antibody-partnering-terms-and-agreements.html
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: https://twitter.com/researchbook
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : http://blog.bharatbook.com/
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.